Supercharged immune cells take on Hard-to-Treat cancers
NCT ID NCT06198296
First seen Nov 03, 2025 · Last updated Jun 12, 2026 · Updated 35 times
Summary
This early-phase trial tests a new type of immunotherapy for adults with solid tumors that have a specific marker called GPC3. Researchers take a patient's own T cells and add three new genes to help them recognize and attack cancer cells more effectively, plus a safety switch to stop them if needed. The study aims to find the safest dose and see if the treatment can shrink tumors. About 21 participants with cancers like liver cancer or Wilms tumor will be enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WILMS TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Hospital
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.